register

News & Trends - Pharmaceuticals

Monash discoveries suggest new breast cancer treatment

Health Industry Hub | October 28, 2020 |

Pharma News: Findings by Monash Biomedicine Discovery Institute (BDI) researchers have pointed to a new combination of treatments that may help breast cancer patients with certain gene mutations.

The study, published in Molecular Cell and led by Dr Antonella Papa, identified potential new treatments for patients who lacked PTEN, a gene that suppresses tumours, and/or have mutations in the cancer gene PI3K.

The researchers demonstrated that the loss of PTEN synergises with mutant PI3K gene in forming tumours in mammary glands. They then found that inhibiting the protein AKT suppressed the growth of PTEN and PI3K mutant mammary organoids.

In a surprising finding, the team also discovered that loss of PTEN function increased levels of the glucocorticoid receptor (GR) and made the tumour cells more prone to death.

The researchers found that combining a treatment called dexamethasone (an anti-inflammatory medication currently available), which activates GR, with an AKT inhibitor (such as Roche’s ipatasertib), better suppressed growth of PTEN/PI3K mutant cancer cells than treatment with a single compound.

The scientists are now testing the efficacy of their combination therapy in pre-clinical animal models with a view to future testing in clinical trials for breast cancer treatment.

PTEN gives instructions for making an enzyme found in most tissues in the body and functions by stopping cells from growing and dividing too rapidly or too uncontrollably. In contrast, PI3K is an enzyme that promotes cell growth and sustains proliferation in cancer when mutated.

Mutations in either PTEN or PI3K alone occur in almost 50% of breast cancer patients. In addition, 10% of breast cancer patients have combined genetic alterations in these two genes.

“These patients could benefit from our findings,” Dr Papa said.

“The finding that GR sensitises PTEN mutant cells to death is absolutely new; it was the opposite of what you would expect,” Dr Papa said.

Dr Papa said while the research had concentrated on breast cancer, the two genes could cause tumours to form in many of the body’s cells.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.